{"id":"W4387809675","doi":"10.1016/j.annonc.2023.10.015","title":"LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Loxo Oncology; Jounce Therapeutics; Genentech; Gilead Sciences; Radius Health; MedImmune; Clovis Oncology; Eisai; Daiichi Sankyo Europe; Sanofi; Daiichi-Sankyo; Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; HER2 negative; Internal medicine; Chemotherapy; Hormone receptor; Breast cancer; Cancer; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009332739,0.0004814187,0.001840692,0.0002599282,0.000149166,0.00002134221,0.0003217427,0.0002580064,0.001807533],"category_scores_gemma":[0.0002376604,0.0003144538,0.0002834178,0.001134644,0.0004048811,0.0001749314,0.00009072785,0.000491159,0.00005096085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000430304,"about_ca_system_score_gemma":0.001604737,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02513886,"about_ca_topic_score_gemma":0.003464586,"domain_scores_codex":[0.9957798,0.001117953,0.001232316,0.0007506746,0.00035667,0.0007626595],"domain_scores_gemma":[0.9955542,0.002713518,0.000626713,0.0005060708,0.0003494182,0.0002500636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8245586,0.004289579,0.0004181495,0.00003841013,0.001989101,0.0003225195,0.003668581,0.00001661143,0.008408664,0.000004766106,0.08668189,0.06960311],"study_design_scores_gemma":[0.9148354,0.01662422,0.02130437,0.0002945916,0.000991794,0.00008254236,0.0006749023,0.0001783303,0.01934286,0.0001140149,0.02512537,0.0004315999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9526737,0.0008801096,0.000005197725,0.0380148,0.0004061103,0.004726343,0.001967005,0.0001010025,0.001225768],"genre_scores_gemma":[0.9610164,0.02419934,0.0002562806,0.006164982,0.0008240074,0.001655299,0.002424514,0.0001020815,0.003357057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09027679,"threshold_uncertainty_score":0.9999307,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06623516967856484,"score_gpt":0.4021662354896132,"score_spread":0.3359310658110483,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}